1183 related articles for article (PubMed ID: 8977706)
1. CD44 expression in melanocytic lesions: a marker of malignant progression?
Harwood CA; Green MA; Cook MG
Br J Dermatol; 1996 Dec; 135(6):876-82. PubMed ID: 8977706
[TBL] [Abstract][Full Text] [Related]
2. CD44 and variants in melanocytic skin neoplasms.
Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
[TBL] [Abstract][Full Text] [Related]
3. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
4. CD44 variant expression in cutaneous T-cell lymphoma.
Orteu CH; Li W; Allen MH; Smith NP; Barker JN; Whittaker SJ
J Cutan Pathol; 1997 Jul; 24(6):342-9. PubMed ID: 9243361
[TBL] [Abstract][Full Text] [Related]
5. CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma.
Fernández-Figueras MT; Ariza A; Calatrava A; Puig L; Fernández-Vasalo A; Ferrándiz C
J Cutan Pathol; 1996 Apr; 23(2):133-9. PubMed ID: 8721447
[TBL] [Abstract][Full Text] [Related]
6. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential.
Manten-Horst E; Danen EH; Smit L; Snoek M; Le Poole IC; Van Muijen GN; Pals ST; Ruiter DJ
Int J Cancer; 1995 Jun; 64(3):182-8. PubMed ID: 7542641
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential.
Seelentag WK; Böni R; Günthert U; Futo E; Burg G; Heitz PU; Roth J
J Cutan Pathol; 1997 Apr; 24(4):206-11. PubMed ID: 9138110
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
10. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44.
Sinn HP; Heider KH; Skroch-Angel P; von Minckwitz G; Kaufmann M; Herrlich P; Ponta H
Breast Cancer Res Treat; 1995; 36(3):307-313. PubMed ID: 8573713
[TBL] [Abstract][Full Text] [Related]
11. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
12. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
13. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
Sanders DS; Blessing K; Hassan GA; Bruton R; Marsden JR; Jankowski J
Mol Pathol; 1999 Jun; 52(3):151-7. PubMed ID: 10621837
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
15. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival.
Dietrich A; Tanczos E; Vanscheidt W; Schöpf E; Simon JC
Eur J Cancer; 1997 May; 33(6):926-30. PubMed ID: 9291817
[TBL] [Abstract][Full Text] [Related]
16. CD44 expression in benign and malignant nevomelanocytic lesions.
Leigh CJ; Palechek PL; Knutson JR; McCarthy JB; Cohen MB; Argenyi ZB
Hum Pathol; 1996 Dec; 27(12):1288-94. PubMed ID: 8958300
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 variant isoforms in malignant melanoma.
Seiter S; Schadendorf D; Herrmann K; Schneider M; Rösel M; Arch R; Tilgen W; Zöller M
Clin Cancer Res; 1996 Mar; 2(3):447-56. PubMed ID: 9816190
[TBL] [Abstract][Full Text] [Related]
18. Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma.
Siiskonen H; Poukka M; Tyynelä-Korhonen K; Sironen R; Pasonen-Seppänen S
BMC Cancer; 2013 Apr; 13():181. PubMed ID: 23560496
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
20. p53 immunoreactivity in human malignant melanoma and dysplastic naevi.
McGregor JM; Yu CC; Dublin EA; Barnes DM; Levison DA; MacDonald DM
Br J Dermatol; 1993 Jun; 128(6):606-11. PubMed ID: 8338744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
